TABLE 1.

Anticancer activity of compounds (µM) (2a-2j).

Compounds	MCF-7 cell line
	GI50 (µM)	TGI (µM)	LC50 (µM)
2a	03.3 ± 0.23	07.3 ± 1.15	07.5 ± 0.03
2b	0.05 ± 0.15	0.65 ± 2.45	0.89 ± 0.28
2c	0.20 ± 0.82	0.50 ± 1.50	0.75 ± 0.35
2d	0.10 ± 0.74	0.70 ± 0.68	1.50 ± 1.40
2e	0.05 ± 0.33	0.06 ± 1.32	0.79 ± 1.25
2f	0.65 ± 0.10	11.0 ± 1.62	20.3 ± 0.24
2g	0.43 ± 0.90	0.75 ± 1.53	15.6 ± 0.72
2h	0.02 ± 0.24	0.15 ± 0.19	0.72 ± 0.31
2i	0.07 ± 0.56	0.60 ± 0.41	2.25 ± 0.31
2j	0.04 ± 0.50	0.29 ± 0.72	9.12 ± 1.21
Doxorubicin	0.04 ± 0.75	0.25 ± 0.23	0.80 ± 0.46

Data represent the mean ± standard deviation (SD) of the mean values of three separate experiments.